The Immsi Group closed 2022 with its best results ever, setting new records for all indicators, including net sales of more than 2 billion euro. Despite continuing geopolitical and macroeconomic complexities, the Group will proceed with its growth program while keeping a constant focus on the efficient management of its business and financial structure to ensure a flexible and immediate response to the challenges of 2023. Consolidated net sales 2,126.1 million euro, the highest figure ever reported, up 24.4% (1,709.6 €/mln in 2021)
EBITDA 287.3 million euro, the highest figure ever reported, up 6% (230.5 €/mln in 2021). EBITDA margin 13.5% (13.5% in 2021)
EBIT 143.7 million euro, up 47% (97.8 €/mln in 2021). EBIT margin 6.8% (5.7% in 2021)
Profit before tax 96.8 million euro (62.2 €/mln in 2021), an improvement of 55.8%, subject to tax of 33 million euro Net profit ante minorities of 63.9 million euro, up 80.4% (35.4 €/mln in 2021); minority interests of 36.8 €/mln at 31.12.2022 (23.2 €/mln in 2021) Immsi Group consolidated net financial position -7 €/mln, an improvement of 32.5 €/mln from -764.2 €/mln at 31.12.2021 Capital expenditure 154.5 million euro Proposed dividend of 3.9 eurocents per share (3 eurocents in the previous financial year)
* * *
Authorisation for the purchase and disposal of own shares Call of the Annual General Meeting Approval of the Non-Financial Disclosure
Mantua, 23 March 2023 – At a meeting today chaired by Roberto Colaninno, the Board of Directors of Immsi S.p.A. (IMS.MI) examined and approved the 2022 draft financial statements1. 1The 2022 draft financial statements and the Immsi Group 2022 consolidated financial statements have been prepared with the XHTML electronic format pursuant to Delegated Regulation (EU) 2019/815 (known as the ESEF Regulation); with the approval of the consolidated financial statements, the related mark-ups using XBRL tags have also been approved.